Hepatocyte Growth Factor and Cardiovascular Autonomic Function
Completed
- Conditions
- Type-2 Diabetes
- Registration Number
- NCT00478127
- Lead Sponsor
- Oita Red Cross Hospital
- Brief Summary
In this study, we tested the hypothesis that elevated HGF is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients not receiving insulin treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Type-2 diabetes
Exclusion Criteria
- Type-1 diabetes
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link elevated HGF to insulin resistance in type 2 diabetes?
How does HGF affect cardiovascular autonomic dysfunction compared to standard diabetes therapies?
Are there biomarkers that correlate with HGF levels and autonomic function in non-insulin treated type 2 diabetics?
What adverse events are associated with HGF modulation in diabetic patients and how are they managed?
What role does HGF play in combination with other growth factors for treating type 2 diabetes complications?